MR-Vac

Phase 3Biologic

GSK

MR-Vac is one of 32 biologic programs targeting Malaria. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalariaActive, not recruiting

DiarrhoeaCompleted

ShigellosisActive, not recruiting

MalariaPhase 3

Active, not recruiting

DiarrhoeaPreclinical

Completed

ShigellosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

MR-Vac

GSK

Phase 3

1 2

Biltricide

Bayer

Preclinical

1 3

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

1 6

IV LBH589

Novartis

Preclinical

1 7

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 8

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Malarone

Medicines for Malaria Venture

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malaria1 trial

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

Completed· GSK logo

GSK·Phase 3·NCT02699099·699 enrolled

Shigellosis1 trial

A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants

Completed· GSK logo

GSK·Phase 2·NCT06663436·200 enrolled

Diarrhoea1 trial

A Staged Phase I/II Observer-blind, Randomised, Controlled, Multi-country Study to Evaluate the Safety, Reactogenicity, and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against S. Sonnei and S. Flexneri, Serotypes 1b, 2a, and 3a, in Adults in Europe (Stage 1) Followed by Age De-escalation From Adults to Children and Infants, and Dose-finding in Infants in Africa (Stage 2)

Completed· GSK logo

GSK·Preclinical·NCT05073003·551 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for MR-Vac. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MR-Vac compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MR-Vac. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: GSK

MR-Vac

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malaria1 trial

Shigellosis1 trial

Diarrhoea1 trial

References

Drug Info

Quick Facts

Related News